Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Tumor treatment is still complicated in the field of medicine. Tumor immunotherapy has been the most interesting research field in cancer therapy. Application of chimeric antigen receptor T (CAR-T) cell therapy has recently achieved excellent clinical outcome in patients, especially those with CD19-positive hematologic malignancies. This phenomenon has induced intense interest to develop CAR-T cell therapy for cancer, especially for solid tumors. However, the performance of CAR-T cell treatment in solid tumor is not as satisfactory as that in hematologic disease. Clinical studies on some neoplasms, such as glioblastoma, ovarian cancer, and cholangiocarcinoma, have achieved desirable outcome. This review describes the history and evolution of CAR-T, generalizes the structure and preparation of CAR-T, and summarizes the latest advances on CAR-T cell therapy in different tumor types. The last section presents the current challenges and prospects of CAR-T application to provide guidance for subsequent research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · cited 2×
“CD19, a surface protein highly expressed on most B-lineage lymphocytes and not on normal tissue outside the B-lineage [44], is the most thoroughly studied target in all of the hematological malignancy-associated antigens, and CD19specific CAR-T cell therapy has demonstrated enormous efficiency in inducing endurable re…”
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“However, cytokine-release syndrome (CRS) was also observed [45].”
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063 · cited 1×
“CD3ζ + CD28/ CD137 (41BB) CD19 B cell lymphomas Enhanced expansion, persistence and anti-tumor effect [28, 40, 86, 87]”
The tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857 · cited 1×
“The tumor microenvironment is a complex and dense fibrotic matrix network composed of malignant and nonmalignant cells, in which the infiltrated CAR-T cells can be inhibited by immunosuppressive cells such as regulatory T cells (Tregs) and myeloid-derived suppressive cells [79].”
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · cited 1×
“treated a patient with advanced follicular lymphoma with anti-CD19-CAR-transduced T cells, and the patient underwent a dramatic regression [51].”
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 1×
“CD3ζ + CD28/ CD137 (41BB) CD19 B cell lymphomas Enhanced expansion, persistence and anti-tumor effect [28, 40, 86, 87]”
Cited by
cGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
“The CAR-T therapy is successful in several hematological diseases, but its application in solid tumors is limited [65].”
BackgroundSelf-citationActivating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Organoid technology and applications in cancer research
Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0662-9 · Cited by 345
Immunotherapy for hepatocellular carcinoma
Zongyi, Y., & Xiaowu, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.12.002 · Cited by 265
Research progress of T cells in cholangiocarcinoma
Wang, Z., Dai, Y., Zhou, Y., Wang, Y., Chen, P., Li, Y., Zhang, Y., Wang, X., Hu, Y., Li, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1453344 · Cited by 2
Metadata
- Authors
- Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G.
- Venue
- Molecular Cancer
- Published
- 2018-05-16
- Volume
- 17
- Issue
- 1
- Pages
- 91-91
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2807276288
- Cited by
- 90
- References
- 14
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. https://app.cochat.ai/papers/10.1186/s12943-018-0840-y
- The paper
- Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G. (2018). Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy. Molecular Cancer. https://doi.org/10.1186/s12943-018-0840-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.